Amylin Obesity Trial Stopped Due to Safety Questions
Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. have become the latest drugmakers to be stymied by safety signals in clinical trials of an obesity candidate. The companies have suspended an ongoing study of pramlintide/metreleptin for obesity.
